Measurable residual disease in relapsed/refractory AML

Measurable residual disease in relapsed/refractory AML

obr

1 year
45 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mark Levis, MD, PhD, explains the impact of measurable residual disease in the clinical outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) at Annual Meeting 2018
Up Next Autoplay